HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis.

AbstractBACKGROUND:
Several modalities have been used for the treatment of cutaneous leishmaniasis (CL) with various results. In vitro and in vivo studies have shown inhibitory effects of azole drugs on Leishmania parasites.
OBJECTIVES:
To evaluate the efficacy and tolerability of oral itraconazole in the treatment of CL caused by L. major.
METHODS:
A total of 200 patients with parasitologically confirmed CL with a duration of less than 45 days from a well known L. major endemic area were included in a randomized, double-blind, placebo-controlled clinical trial. The patients received either itraconazole 200 mg daily (100 patients) or placebo (100 patients) for 8 weeks. The primary outcome measures were clinical cure (complete re-epithelization of all lesions) and parasitological cure at the end of the treatment.
RESULTS:
Eighty-three patients in the itraconazole and 75 patients in the placebo group completed the treatment course. After 8 weeks of treatment, clinical cure was observed in 59% and 53% and parasitological cure was observed in 83% and 76% of patients in the itraconazole and placebo groups, respectively, which were not significantly different. There was no difference in the rate of adverse events.
CONCLUSIONS:
An 8-week course of oral itraconazole was not more effective than placebo in the treatment of CL.
AuthorsM Nassiri-Kashani, A Firooz, A Khamesipour, F Mojtahed, M Nilforoushzadeh, H Hejazi, N Bouzari, Y Dowlati
JournalJournal of the European Academy of Dermatology and Venereology : JEADV (J Eur Acad Dermatol Venereol) Vol. 19 Issue 1 Pg. 80-3 (Jan 2005) ISSN: 0926-9959 [Print] England
PMID15649196 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiprotozoal Agents
  • Itraconazole
Topics
  • Administration, Oral
  • Adolescent
  • Adult
  • Antiprotozoal Agents (therapeutic use)
  • Chi-Square Distribution
  • Child
  • Double-Blind Method
  • Female
  • Humans
  • Itraconazole (therapeutic use)
  • Leishmaniasis, Cutaneous (drug therapy)
  • Male
  • Middle Aged
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: